


OVERVIEW

- 1 LANXESS STOCK
- 2 BUSINESS DEVELOPMENT
- 8 FINANCIAL STATEMENTS
- 14 NOTES
- 16 FURTHER INFORMATION



LANXESS Group Key Data	Q2 2004	Q2 2005	Change	H1 2004	H1 2005	Change
€ million			in %			in %
Sales	1,673	1,859	+11.1	3,283	3,588	+9.3
EBITDA pre exceptionals	115	163	+41.7	280	344	+22.9
EBITDA margin pre exceptionals	6.9%	8.8%		8.5%	9.6%	
EBITDA	97	160	+64.9	262	341	+30.2
EBIT pre exceptionals	41	100	+143.9	111	221	+99.1
EBIT	10	77	*	80	193	+141.3
EBIT margin	0.6%	4.1%		2.4%	5.4%	
Net income	(29)	24		(3)	94	
Earnings per share (€)	(0.40)	0.33		(0.04)	1.29	
Net operating cash flow	72	130	+80.6	5	120	*
Depreciation and amortization	87	83	-4.6	182	148	-18.7
Capital expenditures	54	48	-11.1	104	99	-4.8
Balance sheet total				4,577 <sup>1)</sup>	4,807	+5.0
Stockholders' equity (including minority interest)				1,365 <sup>1)</sup>	1,225	-10.3
Equity ratio				29.8% <sup>1)</sup>	25.5%	
Net financial debt				1,135 <sup>1)</sup>	1,250	+10.1
Number of employees (June 30)				19,659 <sup>1)</sup>	18,725	-4.8

<sup>1)</sup> December 31, 2004

\* change of more than 200%

#### Q2 2005 Events in Brief

##### April

April 11 LANXESS announces its intent to restructure the Fine Chemicals and Styrenic Resins business units and initiates dialog with the works council.

April 18 LANXESS explores potential strategic partnerships for the Paper business unit.

April 26 2004 results published

##### May

May 31 Q1 results and 2005 outlook published

##### June

June 3 Detailed plans are announced for the restructuring of Fine Chemicals and Styrenic Resins.

June 6-7 LANXESS repurchases the mandatory convertible bond and places the associated 11,586,479 shares through an investment bank.

June 15 LANXESS successfully places a benchmark eurobond.

June 16 The stockholder representatives on the LANXESS Supervisory Board are confirmed in office at the company's first Annual Stockholders' Meeting, which is followed by the constituent meeting of the Supervisory Board.

June 20 LANXESS stock is included in the MDAX.

More information on these topics is provided under "Investor Relations" at [www.lanxess.com](http://www.lanxess.com)

#### Note on Financial Data

This interim report as of June 30, 2005, prepared in accordance with the standards of the International Accounting Standards Board (IASB), has been produced independently by the LANXESS Group following its spin-off from the Bayer Group. Except as expressly indicated otherwise, all financial data for the year 2004 are taken from the Combined Financial Statements prepared voluntarily by the LANXESS Group as of December 31, 2004 and June 30, 2004, respectively. The Combined Financial Statements do not constitute consolidated financial statements of LANXESS AG as defined in commercial or company law. Information regarding the way the Combined Financial Statements were prepared and their limited comparability to the consolidated statements is provided in the notes.

# LANXESS STOCK


**LANXESS Stock** LANXESS stock has performed well since its initial listing on January 31, 2005. It rose 16.5% during the second quarter of 2005, opening at €15.91 on April 1 and closing at €18.52 on June 30. A trading volume of some 35 million LANXESS shares was recorded in the three-month period. Market capitalization of LANXESS AG as of June 30, 2005 totaled €1.35 billion.

The German stock market was in cautious mood in the second quarter of 2005, with the difficult economic climate in Europe having a negative effect, particularly in April and May. Market sentiment improved in June.

In the second quarter of 2005, LANXESS stock outperformed its benchmark indices, the MDAX and Dow Jones STOXX 600 Chemicals<sup>SM</sup>.<sup>\*</sup> The capital market responded favorably to the details of LANXESS's restructuring plans, as well as its re-purchase of a mandatory convertible bond and placement of a benchmark eurobond. This response was reflected in the performance of the share price. In June, Deutsche Börse announced LANXESS's inclusion in the selection index MDAX. Our stock has formed part of this index since June 20, 2005.

<sup>\*</sup> The Dow Jones STOXX 600 Chemicals<sup>SM</sup> represents the chemicals-sector companies that are included in a larger index covering the 600 largest European enterprises in 18 different industries. There were 19 companies in the chemicals index as of June 30, 2005.

## Stock Performance in %



LANXESS Stock		Q1 2005	Q2 2005
Capital stock	(€)/no. of shares	73,034,192*	73,034,192**
Market capitalization	€ billion	1.16*	1.35**
High/low for the period	€	17.90/13.63	19.76/15.64
Price at end of quarter	€	15.90*	18.52**
Trading volume	million shares	48.976	35.022
Earnings per share	€	0.96	0.33

\* March 31, 2005

\*\* June 30, 2005

# BUSINESS DEVELOPMENT IN THE SECOND QUARTER OF 2005

## Business Trends in the LANXESS Group

- Second-quarter earnings expand significantly
- EBITDA margin pre exceptionals improves again, up 1.9 points from the prior-year quarter to 8.8%
- “Price before volume” strategy is consistently and successfully implemented
- Sales in Asia-Pacific grow more than 17%

**Sales** In the second quarter of 2005 the LANXESS Group grew sales to €1,859 million, up €186 million from the same

period of 2004. The largest contributions to this 11.1% overall improvement came from the Performance Rubber and Chemical Intermediates segments. Positive price and volume effects outweighed the slightly negative currency effects. In local currencies, sales rose 12.1%. As in the previous quarter, the favorable market environment enabled us to raise selling prices in key areas of our operations, a particularly gratifying development given the high volatility of the raw material and energy markets. The higher prices more than compensated for the medium-term rise in raw material and energy costs. Volume sales also increased despite the consistent implementation of our “price before volume” strategy.

Sales by Segment	Q2 2004	Q2 2005	Change	H1 2004	H1 2005	Change
€ million			in %			in %
Performance Rubber	368	432	+17.4	694	824	+18.7
Engineering Plastics	431	448	+3.9	838	862	+2.9
Chemical Intermediates	320	406	+26.9	686	795	+15.9
Performance Chemicals	490	511	+4.3	968	989	+2.2

**Gross Profit** The 9.1% increase in the cost of sales compared with the second quarter of 2004 was smaller than the growth in business would imply. Gross profit rose by 18.3% from the prior-year period to €440 million. Despite higher raw material costs, the gross profit margin rose to 23.7%, which was 1.5 points ahead of the prior-year quarter. This was the result of passing raw material cost increases through to the market and implementing

our qualitative sales growth strategy in some areas, which improved margins. Dubbed “price before volume,” this strategy, which the LANXESS Group has systematically pursued since becoming economically and legally independent, involves deliberately forgoing business that is not sufficiently profitable. Additional positive momentum resulted from the cost-saving effect of exchange rate fluctuations.

**EBITDA and EBIT** The operating result before depreciation and amortization (EBITDA) pre exceptionals grew 41.7% from the prior-year quarter to €163 million, in light of the improved gross profit margin and function costs that were virtually flat on aggregate. The €23 million in exceptional items reflected in the operating result (EBIT) for the second quarter of 2005 included €20 million in impairment losses recognized on property, plant

and equipment in the Engineering Plastics and Chemical Intermediates segments and under Corporate Center, Services, Non-Core Business, Reconciliation. In addition, expenses were incurred in connection with antitrust investigations in the Performance Rubber and Performance Chemicals segments, as in the second quarter of 2004. These expenses amounted to €3 million in the second quarter of 2005.

EBITDA Pre Exceptionals	Q2 2004	Q2 2005	Change	H1 2004	H1 2005	Change
€ million			in %			in %
Performance Rubber	49	70	+42.9	81	126	+55.6
Engineering Plastics	8	14	+75.0	29	49	+69.0
Chemical Intermediates	31	59	+90.3	112	124	+10.7
Performance Chemicals	43	58	+34.9	98	116	+18.4

**Financial Result** The financial result came in at minus €48 million, compared with minus €27 million in the prior-year quarter. An improvement in income from investments in affiliated companies was offset by slightly higher net interest expense, the expenses incurred for the repurchase and resale of the convertible bond issued in September 2004, and a lower currency translation balance.

**Income before Income Taxes** Income before incomes taxes rose from minus €17 million in the prior-year quarter to €29 million in the second quarter of 2005.

**Net Income** Group net income for the second quarter of 2005 came to €24 million (Q2 2004: minus €29 million after deducting €2 million in income attributable to minority interests). Basic earnings per share rose to €0.33 (Q2 2004: minus €0.40).

### Business Trends by Region

Sales by Market	Q2 2004		Q2 2005		Change in %	H1 2004		H1 2005		Change in %
	€ million	% of total	€ million	% of total		€ million	% of total	€ million	% of total	
EMEA (except Germany)	620	37.1	660	35.5	+6.5	1,231	37.5	1,300	36.2	+5.6
Germany	344	20.5	400	21.5	+16.3	701	21.4	790	22.0	+12.7
Americas	458	27.4	504	27.1	+10.0	871	26.5	953	26.6	+9.4
Asia-Pacific	251	15.0	295	15.9	+17.5	480	14.6	545	15.2	+13.5
	<b>1,673</b>	<b>100.0</b>	<b>1,859</b>	<b>100.0</b>	<b>+11.1</b>	<b>3,283</b>	<b>100.0</b>	<b>3,588</b>	<b>100.0</b>	<b>+9.3</b>

Compared with the prior-year quarter LANXESS grew sales in the EMEA (Europe, Middle East, Africa) region, excluding Germany, by 6.5% to €660 million, with selling-price increases continuing to have a positive impact. Business expanded at an above-average rate in Belgium and Italy in particular. The EMEA region accounted for 35.5% of total sales, compared with 37.1% in the same period last year.

Sales in Germany rose 16.3% to €400 million, with the highest growth recorded by the Performance Rubber and Engineering Plastics segments. A technical effect arising from the switch from Combined Financial Statements to consolidated reporting by the independent LANXESS Group helped to boost the sales figure for Germany, depressing it correspondingly in the other regions. The proportion of total business transacted with customers in Germany advanced slightly to 21.5%, from 20.5% in the second quarter of 2004.

LANXESS grew second-quarter sales in the Americas region by 10.0% to €504 million. In local currencies the increase came to 12.2%, with the Performance Rubber and Chemical Intermediates segments making the largest contributions. Business in the United States and Mexico was up significantly, aided by the strength of those countries' economies. The Americas region accounted for 27.1% of Group sales, against 27.4% in the prior-year quarter.

With business in Asia-Pacific propelled by the continuing rapid pace of economic growth, LANXESS grew sales there by 17.5% from the prior-year period, to €295 million. In local currencies, sales rose by 21.2%. An upward trend was recorded in all segments, especially Engineering Plastics and Chemical Intermediates, which posted substantial sales growth in China and Thailand, in particular. The Asia-Pacific region contributed 15.9% of total sales, compared with 15.0% in the prior-year quarter.

## Segment Information

Performance Rubber	Q2 2004		Q2 2005		Change	H1 2004		H1 2005		Change
	€ million	in % of sales	€ million	in % of sales	in %	€ million	in % of sales	€ million	in % of sales	in %
Sales	368		432		+17.4	694		824		+18.7
EBITDA pre exceptionals	49	13.3	70	16.2	+42.9	81	11.7	126	15.3	+55.6
EBITDA	38	10.3	68	15.7	+78.9	70	10.1	124	15.0	+77.1
EBIT pre exceptionals	25	6.8	54	12.5	+116.0	37	5.3	95	11.5	+156.8
EBIT	14	3.8	52	12.0	*	26	3.7	93	11.3	*

\* change of more than 200%

Sales of the Performance Rubber segment in the second quarter of 2005 rose 17.4% to €432 million, from €368 million in the prior-year quarter. Price increases were successfully implemented to pass higher raw material and energy costs through to the market, this factor alone boosting sales by 12.5%. In addition, continuing brisk demand for rubber contributed to a 6.1% volume-based sales increase that more than offset a 1.2% decline due to currency effects.

EBITDA pre exceptionals in the Performance Rubber segment rose by €21 million to €70 million thanks to an improved product

mix and our success in raising selling prices. Cost savings also contributed to the higher earnings.

The EBITDA margin pre exceptionals in the Performance Rubber segment improved by 2.9 points to 16.2%.

As in the prior-year quarter, the exceptional items in this segment consisted solely of expenses incurred in the course of antitrust investigations in the Technical Rubber Products business unit. These expenses amounted to €2 million (Q2 2004: €11 million).

Engineering Plastics	Q2 2004		Q2 2005		Change	H1 2004		H1 2005		Change
	€ million	in % of sales	€ million	in % of sales	in %	€ million	in % of sales	€ million	in % of sales	in %
Sales	431		448		+3.9	838		862		+2.9
EBITDA pre exceptionals	8	1.9	14	3.1	+75.0	29	3.5	49	5.7	+69.0
EBITDA	8	1.9	14	3.1	+75.0	29	3.5	49	5.7	+69.0
EBIT pre exceptionals	3	0.7	6	1.3	+100.0	6	0.7	32	3.7	*
EBIT	17	3.9	(6)	(1.3)		20	2.4	18	2.1	-10.0

\* change of more than 200%

Sales in the Engineering Plastics segment showed a €17 million year-on-year increase in the second quarter of 2005 to €448 million, with negative volume effects of 1.7% offset by positive price effects of 6.6%. Negative currency effects shaved 1.0% off sales. The pillar of this segment's sales growth was the Semi-Crystalline Products business unit, which recorded an upward business trend and, as a result, high capacity utilization. On top of considerable growth in volumes, price increases were also implemented. As was already the case in the first quarter of 2005, slight price increases in the Styrenic Resins business were accompanied by a drop in volumes, an effect that was in line with

our strategy of forgoing unprofitable sales. In the Fibers business unit, both volumes and selling prices receded once again, with the unit suffering as it had in previous quarters from global overcapacities and the resulting intense pressure on prices.

EBITDA pre exceptionals in the Engineering Plastics segment rose by €6 million to €14 million, driven mainly by the price increases in the Semi-Crystalline Products business unit, which served to pass the higher raw material costs through to the market. Cost-saving measures also had a positive impact on earnings.

Although the EBITDA margin pre exceptionals edged slightly higher, up 1.2 points to 3.1%, it remains entirely unsatisfactory. The Engineering Plastics segment continues to deliver the lowest profit contributions in the LANXESS Group, in both absolute and relative terms. This underscores the need for the restructuring measures agreed upon in the second quarter of 2005 for the Styrenic Resins business unit in order to improve its competitiveness. The restructuring will include a thorough realignment

of operations at the European Styrenic Resins facilities in Dormagen, Germany, and Tarragona, Spain.

EBIT was impacted by impairment charges of €3 million in the Styrenic Resins business unit and €9 million in the Fibers business unit. In the prior-year period there had been a €14 million boost to earnings from reversals of impairment losses previously recognized on assets of the Styrenic Resins business unit.

Chemical Intermediates	Q2 2004		Q2 2005		Change	H1 2004		H1 2005		Change
	€ million	in % of sales	€ million	in % of sales	in %	€ million	in % of sales	€ million	in % of sales	in %
Sales	320		406		+26.9	686		795		+15.9
EBITDA pre exceptionals	31	9.7	59	14.5	+90.3	112	16.3	124	15.6	+10.7
EBITDA	31	9.7	59	14.5	+90.3	112	16.3	124	15.6	+10.7
EBIT pre exceptionals	8	2.5	40	9.9	*	56	8.2	90	11.3	+60.7
EBIT	2	0.6	34	8.4	*	50	7.3	81	10.2	+62.0

\* change of more than 200%

Sales in the Chemical Intermediates segment in the second quarter of 2005 were up 26.9% from the prior-year quarter, due to a volume-based growth of 20.3% and a price-based increase of 7.5%. Currencies had a 0.9% negative effect. Substantial price- and volume-based gains were achieved in the Basic Chemicals business unit, with Inorganic Pigments also recording small increases from both prices and volumes. Due to an improved situation for agrochemicals and pharmaceutical intermediates, the Fine Chemicals business unit achieved strong, largely volume-driven sales growth from the weak prior-year quarter.

Fueled mainly by improved capacity utilization and somewhat better cost structures, EBITDA pre exceptionals in the Chemical Intermediates segment rose 90.3% year on year. However, higher selling prices did not fully compensate for the higher cost of raw

materials in the Inorganic Pigments business unit. The EBITDA margin pre exceptionals in the Chemical Intermediates segment advanced from 9.7% to 14.5%.

As in the prior-year quarter, EBIT was diminished by impairment charges in the Fine Chemicals business unit. These charges amounted to €6 million for the second quarter of 2005. LANXESS decided on a comprehensive package of measures for this business unit in the second quarter of 2005. In addition to a spin-off of the business to a separate legal entity, the strategy includes the closure of several unprofitable facilities, combined with the active management of both product and customer portfolios. The goal of the restructuring is to make the Fine Chemicals business unit internationally competitive for the long term.

Performance Chemicals	Q2 2004		Q2 2005		Change	H1 2004		H1 2005		Change
	€ million	in % of sales	€ million	in % of sales	in %	€ million	in % of sales	€ million	in % of sales	in %
Sales	490		511		+4.3	968		989		+2.2
EBITDA pre exceptionals	43	8.8	58	11.4	+34.9	98	10.1	116	11.7	+18.4
EBITDA	36	7.3	57	11.2	+58.3	91	9.4	115	11.6	+26.4
EBIT pre exceptionals	25	5.1	42	8.2	+68.0	58	6.0	85	8.6	+46.6
EBIT	(3)	(0.6)	41	8.0		30	3.1	84	8.5	+180.0

Sales of the Performance Chemicals segment grew 4.3% from the prior-year period, to €511 million. In local currencies, the increase came to 5.4%. There was a 7.2% sales increase from higher prices but a 1.8% decrease from lower volumes. The Rubber Chemicals, Ion Exchange Resins and Leather business units, in particular, succeeded in passing the higher raw material costs through to the market. Volume growth was also achieved, especially by the Leather business unit. The Textile Processing Chemicals business unit once again posted a decline in sales in Europe and the Americas.

### Corporate Center, Services, Non-Core Business,

**Reconciliation** Departing from the presentation in the 2004 Annual Report, corporate costs are no longer allocated among the operating segments. As of fiscal 2005 they are instead reported collectively under a segment named "Corporate Center, Services, Non-Core Business, Reconciliation," facilitating a comparison of performance across LANXESS's operating segments.

### Financial Condition

**Balance Sheet Structure** As of June 30, 2005 the LANXESS Group had total assets of €4,807 million, an increase of 5.0% compared with December 31, 2004. With noncurrent assets almost unchanged, this growth was mainly attributable to current assets, which increased by 14.0% to €3,104 million. Inventories were up 14.6% to €1,319 million, chiefly because of exchange rate movements, considerably higher raw material costs and anticipated maintenance shutdowns. Trade receivables rose 6.6% to €1,212 million, also because of exchange rate movements and due to the business expansion in the first half of 2005. Liquid assets stood at €178 million, compared with €72 million on December 31, 2004. Both the decline in deferred tax assets and the increase in deferred tax liabilities resulted from an adjustment of these items – not recognized in income – necessitated by the transition from the Combined Financial

Effective cost management, particularly in the Rubber Chemicals and RheinChemie business units, was the main factor behind a 34.9% increase in EBITDA pre exceptionals for the Performance Chemicals segment. The EBITDA margin pre exceptionals rose 2.6 points to 11.4%.

The €1 million in exceptional items for this segment relates entirely to expenses incurred in connection with antitrust investigations in the Rubber Chemicals business unit. The €28 million in exceptional items in the prior-year quarter included €7 million in expenses for these investigations as well as a €21 million write-down of goodwill in the RheinChemie business unit.

The figures already published for the individual quarters of 2004 have been adjusted accordingly. The amount of corporate costs reclassified for the second quarter of 2004 was €16 million, with the cumulative reclassification for the first six months of 2004 standing at €32 million. The €2 million in exceptional items for this segment in the second quarter of 2005 relates to impairment charges taken for unused assets.

Statements as of December 31, 2004 to the consolidated interim financial statements of the LANXESS Group as of June 30, 2005. Further details are given in the notes.

Stockholders' equity including minority interests shrank by 10.3% from December 31, 2004 to €1,225 million on June 30, 2005, giving a 25.5% equity ratio. The decrease is due mainly to the direct recognition in equity of deferred-tax adjustments. This item is reflected in the changes-in-equity statement and explained in the notes.

Liabilities rose by 8.6% to €3,384 million, with a decline in trade payables offset mainly by an increase in financial liabilities and in other provisions. The growth in other provisions results from an increase in short-term personnel-related provisions, tax provisions and provisions for invoices not yet received.



**Liquidity and Capital Resources** Net operating cash flow in the first half of 2005 improved by a substantial €115 million compared with the same period of 2004, mainly due to the €113 million growth in EBIT. An additional factor was the smaller increase in working capital, including other net current assets, than in the prior-year period.

With respect to investing activities, there was a net outflow of €91 million, compared with €112 million in the first half of 2004. The €99 million in cash outflow for additions to property, plant, equipment and intangible assets was somewhat below the prior-year period and below the €148 million in depreciation and amortization. Capital spending in the first half of 2005 was attributable primarily to the Chemical Intermediates and Performance Chemicals segments, including in particular the Basic Chemicals business unit in Leverkusen and the Material Protection Products business unit in Dormagen, respectively. Substantial capital expenditures were also made for the Performance Rubber segment in Belgium.

The €8 million in ancillary cost of acquisition (land transfer tax) incurred for the purchase of land and buildings at production sites in Germany, reported entirely as capital expenditures of the Reconciliation segment in the first quarter of 2005, was reclassified as capital expenditures of the operating segments as of

**Outlook** We believe the upward trend in the world economy and our market environment will continue in the months ahead. Against this background and with LANXESS using its independence to realign the business, we expect to see a continuing improvement in performance. We therefore expect that EBITDA pre exceptionals will grow to between €550 million and €560 million for the full year 2005, compared with €447 million in 2004.

We predict rather more moderate sales growth for the remainder of 2005, in light of the strong second half we enjoyed last year and also our "price before volume" strategy. Full-year sales should show an increase from 2004.

June 30, 2005. The land and buildings transferred to the LANXESS Group as part of the spin-off had already been assigned to LANXESS for economic purposes and recognized at cost less accumulated depreciation in the Combined Financial Statements as of December 31, 2004. They are reflected in the consolidated balance sheet as of June 30, 2005 at their net carrying amounts.

Net cash provided by financing activities came to €72 million. The financial liabilities to the Bayer Group that existed as of December 31, 2004 were repaid in full, and the revolving credit line arranged with an international bank consortium in December 2004 was drawn on for the first time. The proceeds from the issuance of the €500 million benchmark eurobond, which matures in 2012 and carries a coupon of 4.125%, were used to repay existing financial liabilities. This bond strengthens the company's balance sheet for the long term. The total of interest paid and other financial disbursements, including expenses from the repurchase and resale of the convertible bond in June 2005, came to €53 million.

Liquid assets as of June 30, 2005 totaled €178 million, a €106 million increase from year-end 2004. Net financial debt grew 10.1% to €1,250 million, from €1,135 million on December 31, 2004, mainly because of the increase in working capital and growth in business.

Capital expenditures are likely to be at the lower end of our previous forecast of €250 million to €270 million.

The already announced restructuring of our Styrenic Resins and Fine Chemicals business units will begin to adversely affect earnings in the third quarter. LANXESS also plans to take further action to reach the goals set for the LANXESS Group, which has been independent since early 2005. Earnings are therefore likely to be diminished by additional restructuring charges.

# LANXESS GROUP STATEMENTS OF INCOME

	Q2 2004		Q2 2005		H1 2004		H1 2005	
	€ million	in % of sales	€ million	in % of sales	€ million	in % of sales	€ million	in % of sales
<b>Sales</b>	<b>1,673</b>		<b>1,859</b>		<b>3,283</b>		<b>3,588</b>	
Cost of sales	(1,301)	(77.8)	(1,419)	(76.3)	(2,542)	(77.4)	(2,706)	(75.4)
<b>Gross profit</b>	<b>372</b>	<b>22.2</b>	<b>440</b>	<b>23.7</b>	<b>741</b>	<b>22.6</b>	<b>882</b>	<b>24.6</b>
Selling expenses	(218)	(13.0)	(221)	(11.9)	(424)	(12.9)	(432)	(12.0)
Research and development expenses	(31)	(1.9)	(28)	(1.5)	(66)	(2.0)	(54)	(1.5)
General administration expenses	(72)	(4.3)	(71)	(3.8)	(131)	(4.0)	(142)	(4.0)
Other operating expenses/income – net	(41)	(2.5)	(43)	(2.3)	(40)	(1.2)	(61)	(1.7)
<b>Operating result (EBIT)</b>	<b>10</b>	<b>0.6</b>	<b>77</b>	<b>4.1</b>	<b>80</b>	<b>2.4</b>	<b>193</b>	<b>5.4</b>
Income/expense from investments in affiliated companies – net	0	0.0	3	0.2	0	0.0	8	0.2
Interest expense – net	(9)	(0.5)	(13)	(0.7)	(28)	(0.9)	(23)	(0.6)
Other financial expense/income – net	(18)	(1.1)	(38)	(2.0)	(20)	(0.6)	(55)	(1.5)
<b>Financial result</b>	<b>(27)</b>	<b>(1.6)</b>	<b>(48)</b>	<b>(2.6)</b>	<b>(48)</b>	<b>(1.5)</b>	<b>(70)</b>	<b>(2.0)</b>
<b>Income (loss) before income taxes</b>	<b>(17)</b>	<b>(1.0)</b>	<b>29</b>	<b>1.6</b>	<b>32</b>	<b>1.0</b>	<b>123</b>	<b>3.4</b>
Income taxes	(10)	(0.6)	(5)	(0.3)	(31)	(0.9)	(28)	(0.8)
<b>Income (loss) after taxes</b>	<b>(27)</b>	<b>(1.6)</b>	<b>24</b>	<b>1.3</b>	<b>1</b>	<b>0.0</b>	<b>95</b>	<b>2.6</b>
Minority interests	(2)	(0.1)	0	0.0	(4)	(0.1)	(1)	0.0
<b>Net income (loss)</b>	<b>(29)</b>	<b>(1.7)</b>	<b>24</b>	<b>1.3</b>	<b>(3)</b>	<b>(0.1)</b>	<b>94</b>	<b>2.6</b>
<b>Basic earnings per share (€)</b>	<b>(0.40)</b>		<b>0.33</b>		<b>(0.04)</b>		<b>1.29</b>	
<b>Diluted earnings per share (€)</b>	<b>(0.40)</b>		<b>0.27</b>		<b>(0.04)</b>		<b>1.13</b>	

# LANXESS GROUP BALANCE SHEETS

	December 31, 2004	June 30, 2005
€ million		
<b>ASSETS</b>		
<b>Noncurrent assets</b>		
Intangible assets	65	60
Property, plant and equipment	1,521	1,517
Investments in associates	44	52
Other financial assets	41	38
	<b>1,671</b>	<b>1,667</b>
<b>Current assets</b>		
Inventories	1,151	1,319
Receivables and other assets		
Trade receivables	1,137	1,212
Other receivables and other assets	363	395
	1,500	1,607
Liquid assets	72	178
	<b>2,723</b>	<b>3,104</b>
<b>Deferred taxes</b>	<b>172</b>	<b>18</b>
<b>Prepaid expenses</b>	<b>11</b>	<b>18</b>
<b>Total assets</b>	<b>4,577</b>	<b>4,807</b>
<b>STOCKHOLDERS' EQUITY AND LIABILITIES</b>		
<b>Stockholders' equity</b>		
Capital stock and reserves of LANXESS AG	836	836
Retained earnings	896	631
Net income (loss)	(12)	94
Other comprehensive income (loss)	(369)	(351)
Minority interests	14	15
	<b>1,365</b>	<b>1,225</b>
<b>Liabilities</b>		
<b>Noncurrent liabilities</b>		
Provisions for pensions and other post-employment benefits	418	449
Other provisions	238	224
Financial liabilities	131	634
Other liabilities	1	1
	788	1,308
<b>Current liabilities</b>		
Other provisions	243	359
Financial liabilities	1,076	794
Trade payables	820	735
Other liabilities	189	188
	2,328	2,076
	<b>3,116</b>	<b>3,384</b>
<b>Deferred taxes</b>	<b>55</b>	<b>152</b>
<b>Deferred income</b>	<b>41</b>	<b>46</b>
<b>Total stockholders' equity and liabilities</b>	<b>4,577</b>	<b>4,807</b>

# LANXESS GROUP STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

	Capital stock and reserves of LANXESS AG	Retained earnings	Net income (loss)	Other comprehensive income (loss) <sup>1,2)</sup>	Total	Minority interests <sup>2)</sup>	Total stockholders' equity
€ million							
<b>December 31, 2003</b>	<b>836</b>	<b>1,893</b>	<b>(997)</b>	<b>(354)</b>	<b>1,378</b>	<b>23</b>	<b>1,401</b>
Dividend payments					0		0
Allocation to retained earnings		(997)	997		0		0
Exchange differences				(16)	(16)		(16)
Other changes in stockholders' equity				1	1	(8)	(7)
Net income (loss)			(3)		(3)	4	1
<b>June 30, 2004</b>	<b>836</b>	<b>896</b>	<b>(3)</b>	<b>(369)</b>	<b>1,360</b>	<b>19</b>	<b>1,379</b>
<b>December 31, 2004</b>	<b>836</b>	<b>896</b>	<b>(12)</b>	<b>(369)</b>	<b>1,351</b>	<b>14</b>	<b>1,365</b>
Dividend payments					0	(2)	(2)
Allocation to retained earnings		(12)	12		0		0
Exchange differences				32	32		32
Other changes in stockholders' equity		(253)		(14)	(267)	2	(265)
Net income			94		94	1	95
<b>June 30, 2005</b>	<b>836</b>	<b>631</b>	<b>94</b>	<b>(351)</b>	<b>1,210</b>	<b>15</b>	<b>1,225</b>

<sup>1)</sup> This item consists mainly of currency translation adjustments and changes in the fair values of financial instruments that are not recognized in income.

<sup>2)</sup> 2003 figures restated

# LANXESS GROUP STATEMENTS OF CASH FLOWS

	H1 2004	H1 2005
€ million		
<b>Operating result (EBIT)</b>	<b>80</b>	<b>193</b>
Income taxes	(37)	(39)
Depreciation and amortization	182	148
Change in pension provisions	(16)	6
(Gains) losses on retirements of property, plant and equipment	4	(1)
<b>Gross cash flow</b>	<b>213</b>	<b>307</b>
Change in inventories	(73)	(115)
Change in trade receivables	(147)	(28)
Change in trade payables	31	(120)
Changes in other net current assets	(19)	76
<b>Net cash provided by operating activities</b>	<b>5</b>	<b>120</b>
Cash outflow for additions to property, plant and equipment	(104)	(99)
Cash inflow from sales of property, plant and equipment	43	5
Cash outflow for additions to financial assets	(51)	0
Interest and dividends received	0	3
<b>Net cash used in investing activities</b>	<b>(112)</b>	<b>(91)</b>
Dividends paid to minority interests	0	(2)
Proceeds from borrowings	259	844
Repayments of borrowings	(62)	(717)
Interest paid and other financial disbursements	(35)	(53)
<b>Net cash provided by financing activities</b>	<b>162</b>	<b>72</b>
<b>Change in cash and cash equivalents from business activities</b>	<b>55</b>	<b>101</b>
<b>Cash and cash equivalents as of January 1</b>	<b>13</b>	<b>72</b>
Change in cash and cash equivalents due to changes in scope of consolidation	1	0
Other changes in cash and cash equivalents	0	4
<b>Cash and cash equivalents as of June 30</b>	<b>69</b>	<b>177</b>
Marketable securities and other instruments	0	1
<b>Liquid assets as per balance sheets</b>	<b>69</b>	<b>178</b>

# KEY DATA BY SEGMENT AND REGION

## Key Data by Segment

Second Quarter	Q2 2004	Q2 2005	Q2 2004	Q2 2005	Q2 2004	Q2 2005
€ million	<b>Performance Rubber</b>		<b>Engineering Plastics</b>		<b>Chemical Intermediates</b>	
Sales	368	432	431	448	320	406
EBITDA pre exceptionals	49	70	8	14	31	59
EBITDA margin pre exceptionals	13.3%	16.2%	1.9%	3.1%	9.7%	14.5%
EBITDA	38	68	8	14	31	59
Operating result (EBIT) pre exceptionals	25	54	3	6	8	40
Operating result (EBIT)	14	52	17	(6)	2	34
Capital expenditures	18	15	8	9	18	18
Depreciation and amortization	24	16	(9)	20	29	25

First Half	H1 2004	H1 2005	H1 2004	H1 2005	H1 2004	H1 2005
€ million	<b>Performance Rubber</b>		<b>Engineering Plastics</b>		<b>Chemical Intermediates</b>	
Sales	694	824	838	862	686	795
EBITDA pre exceptionals	81	126	29	49	112	124
EBITDA margin pre exceptionals	11.7%	15.3%	3.5%	5.7%	16.3%	15.6%
EBITDA	70	124	29	49	112	124
Operating result (EBIT) pre exceptionals	37	95	6	32	56	90
Operating result (EBIT)	26	93	20	18	50	81
Capital expenditures	29	24	17	14	28	27
Depreciation and amortization	44	31	9	31	62	43
Number of employees (June 30)	3,163 <sup>1)</sup>	3,013	3,652 <sup>1)</sup>	3,533	3,819 <sup>1)</sup>	3,635

<sup>1)</sup> December 31, 2004

## Key Data by Region

Second Quarter	Q2 2004	Q2 2005	Q2 2004	Q2 2005	Q2 2004	Q2 2005
€ million	<b>EMEA (except Germany)</b>		<b>Germany</b>		<b>Americas</b>	
Sales by market	620	660	344	400	458	504
Proportion of Group sales	37.1%	35.5%	20.5%	21.5%	27.4%	27.1%

First Half	H1 2004	H1 2005	H1 2004	H1 2005	H1 2004	H1 2005
€ million	<b>EMEA (except Germany)</b>		<b>Germany</b>		<b>Americas</b>	
Sales by market	1,231	1,300	701	790	871	953
Proportion of Group sales	37.5%	36.2%	21.4%	22.0%	26.5%	26.6%
Number of employees (June 30)	3,717 <sup>1)</sup>	3,317	10,098 <sup>1)</sup>	9,819	3,920 <sup>1)</sup>	3,822

<sup>1)</sup> December 31, 2004

	Q2 2004	Q2 2005	Q2 2004	Q2 2005	Q2 2004	Q2 2005
	<b>Performance Chemicals</b>		<b>Corporate Center, Services, Non-Core Business, Reconciliation</b>		<b>LANXESS</b>	
	490	511	64	62	1,673	1,859
	43	58	(16)	(38)	115	163
	8.8%	11.4%			6.9%	8.8%
	36	57	(16)	(38)	97	160
	25	42	(20)	(42)	41	100
	(3)	41	(20)	(44)	10	77
	10	14	0	(8)	54	48
	39	16	4	6	87	83

	H1 2004	H1 2005	H1 2004	H1 2005	H1 2004	H1 2005
	<b>Performance Chemicals</b>		<b>Corporate Center, Services, Non-Core Business, Reconciliation</b>		<b>LANXESS</b>	
	968	989	97	118	3,283	3,588
	98	116	(40)	(71)	280	344
	10.1%	11.7%			8,5%	9,6%
	91	115	(40)	(71)	262	341
	58	85	(46)	(81)	111	221
	30	84	(46)	(83)	80	193
	21	26	9	8	104	99
	61	31	6	12	182	148
	5,140 <sup>1)</sup>	4,872	3,885 <sup>1)</sup>	3,672	19,659 <sup>1)</sup>	18,725

	Q2 2004	Q2 2005	Q2 2004	Q2 2005
	<b>Asia-Pacific</b>		<b>LANXESS</b>	
	251	295	1,673	1,859
	15.0%	15.9%		

	H1 2004	H1 2005	H1 2004	H1 2005
	<b>Asia-Pacific</b>		<b>LANXESS</b>	
	480	545	3,283	3,588
	14.6%	15.2%		
	1,924 <sup>1)</sup>	1,767	19,659 <sup>1)</sup>	18,725

# NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2005

**Recognition and Valuation Principles** Like the Combined Financial Statements for fiscal 2004, the unaudited consolidated financial statements as of June 30, 2005 were prepared in accordance with the standards of the International Accounting Standards Board (IASB). The recognition and valuation principles applied were the same as those used for the 2004 Combined Financial Statements, with the exception that effective

January 1, 2005, goodwill resulting from business combinations agreed upon prior to March 31, 2004 is also no longer amortized but instead tested annually for possible impairment. IAS 34 (Interim Financial Reporting) was also applied. The classification of assets and liabilities according to maturity as required by IAS 1 (Presentation of Financial Statements) will be undertaken in the annual financial statements for 2005.

## **Transition from Combined Financial Statements to Consolidated Financial Statements of the LANXESS**

**Group** The Combined Financial Statements as of December 31, 2004 were derived from the consolidated financial statements of the Bayer Group in order to provide a historical record of LANXESS financial data ahead of the spin-off. The interim financial statements as of June 30, 2005 were prepared independently by the LANXESS Group following its spin-off from Bayer.

The need for these adjustments arose partly because the opening balance sheet had to reflect the amount of loss carry-forwards actually transferred to LANXESS in the course of the spin-off pursuant to tax regulations, and this amount differed from that previously allocated to LANXESS on an accountability basis for the purpose of the Combined Financial Statements. There were also some changes in deferred taxes as a result of timing differences.

As a result of the transition from the Combined Financial Statements – on which calculations had to be based prior to the spin-off – to consolidated Group statements, the stockholders' equity of the LANXESS Group decreased by €253 million, mainly because of adjustments to deferred taxes that are not recognized in income.

The minority-interest component of stockholders' equity reported as of June 30, 2005 also reflects the currency translation adjustments attributable to minority interests. This had the effect of reducing minority interests compared with the amount reported in the Combined Financial Statements as of December 31, 2003 by €20 million and increasing total stockholders' equity – excluding minority interests – by the same amount. The figures for December 31, 2004 were restated accordingly.

**Scope of Consolidation** The consolidated financial statements of the LANXESS Group include the parent company LANXESS AG along with all of its material domestic and foreign subsidiaries. Two companies were consolidated for the first time in the second quarter of 2005: LANXESS Finance B.V., Ede, Netherlands, which was founded on June 6, 2005 in connection with the issuance of the benchmark eurobond and will serve in the future as the LANXESS Group's financing and service company, and Perlon-Monofil GmbH (formerly 1. BCheV GmbH), Dormagen, Germany, which acquired the Perlon monofilament business from Dorlastan Fibers & Monofil GmbH effective

April 1, 2005. Since both companies were formed on the basis of asset transfers from other fully consolidated companies, a statement of changes in Group assets and liabilities resulting from changes in the scope of consolidation is not provided.

Sixty-one companies were fully consolidated into the financial statements of the LANXESS Group as of June 30, 2005. In addition, unchanged from December 31, 2004, Chrome International South Africa (Pty) Ltd. was included by proportionate consolidation, while Bayer Industry Services GmbH & Co. OHG was included at equity.



**Capital Stock** On June 16, 2005 the Annual Stockholders' Meeting of LANXESS AG approved a €20,000,000 contingent capital increase for the issuance of up to €20,000,000 new no-par bearer shares. The purpose of this contingent capital increase was to enable shares to be issued to the holders of the convertible bond issued by the company pursuant to the Stockholders'

**Employees** The LANXESS Group had a total of 18,725 employees on June 30, 2005, compared with 19,659 on December 31, 2004 and 18,799 on March 31, 2005. In the Combined Financial Statements as of December 31, 2004,

**Supervisory Board** The following individuals were elected at the Annual Stockholders' Meeting held on June 16, 2005 to serve as stockholder representatives on the LANXESS AG Supervisory Board:

Dr. Rolf Stomberg (Chairman)  
 Dr. Friedrich Janssen  
 Dr. Jürgen F. Kammer  
 Robert J. Koehler  
 Rainer Laufs  
 Lutz Lingnau  
 Prof. h.c. (CHN) Dr. Ulrich Middelmann  
 Dr. Sieghardt Rometsch

**Earnings per Share** Basic earnings per share were determined by dividing Group net income by the number of shares in issue during the reporting period, namely the 73,034,192 shares admitted to trading on the Frankfurt Stock Exchange in January 2005 following the spin-off. Computation of diluted

### Subsequent Events

**Capital Increase from Contingent Capital** Following the bondholder's exercise of its right to convert the mandatory convertible bond, the capital stock of LANXESS AG was increased on July 20, 2005 by €11,586,478 to €84,620,670 through

Meeting resolution of September 15, 2004 in the case of either voluntary or mandatory conversion. The contingent capital increase may only be implemented to the extent the holders of the convertible bond exercise their conversion rights or fulfill their conversion obligation (see Subsequent Events).

some 600 employees of Bayer companies were allocated to the LANXESS Group for statistical purposes because they worked in agency business for LANXESS. As of the date of the spin-off, these individuals are no longer assigned to LANXESS.

The employee representatives on the LANXESS AG Supervisory Board are:

Ralf Deitz (Vice Chairman)  
 Wolfgang Blossey  
 Werner Czaplík  
 Dr. Rudolf Fauss  
 Ulrich Freese  
 Rainer Hippler  
 Hans-Jürgen Schicker  
 Gisela Seidel

The term of office of all Supervisory Board members runs until the end of the Annual Stockholders' Meeting that resolves on the ratification of their actions with respect to the 2009 fiscal year.

earnings per share is based on this number of shares plus the number of additional shares that could be issued upon the exercise of the conversion rights attaching to the convertible bond issued by LANXESS AG on September 15, 2004.

the issuance of 11,586,478 no-par bearer shares, each representing €1.00 of the capital stock. These new shares, which are entitled to any dividends from January 1, 2005 onward, were admitted to trading on German stock exchanges on July 22, 2005.

**Contact**

Please do not hesitate to contact us if you have any questions or comments.

Contact in Corporate Communications

Christoph Sieder

Head of Corporate Communications

Tel. +49 (0) 214 30 43024

E-mail: [mediarelations@lanxess.com](mailto:mediarelations@lanxess.com)

Contact in Investor Relations

Michael Pontzen

Head of Investor Relations

Tel. +49 (0) 214 30 77141

E-mail: [ir@lanxess.com](mailto:ir@lanxess.com)

**Masthead**

LANXESS AG

51369 Leverkusen

Germany

Tel. +49 (0) 214 30 0

[www.lanxess.com](http://www.lanxess.com)

Concept and design

Kirchhoff Consult AG, Hamburg,

Germany

Photography

Claudia Kempf, Wuppertal,

Germany

English edition

Bayer Industry Services GmbH & Co. OHG

Central Language Service

Printed by

Kunst- und Werbedruck, Bad Oeynhausen,

Germany

**Financial Calendar for 2005**

November 17

Interim Report Q3 2005

**Disclaimer**


This publication contains certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the company to differ materially from the estimations expressed or implied herein. The company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed herein or the actual occurrence of the forecasted developments.

No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither the Company nor any of its parent or subsidiary undertakings nor any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.



**PUBLISHER**

LANXESS AG  
51369 Leverkusen  
Germany  
Tel. +49 (0) 214 30 0  
[www.lanxess.com](http://www.lanxess.com)



**LANXESS**  
Energizing Chemistry